By Daniella Parra
Swiss life sciences company Lunaphore Technologies SA has agreed to be acquired by Bio-Techne Corporation, (NASDAQ:TECH) a global provider of tools and reagents for research and diagnostics.
Lunaphore’s advanced microfluidic technology enables the analysis of biomarkers in tumors and tissues at single-cell resolution, supporting therapeutic development and improving patient outcomes.
“We are truly excited to be joining Bio-Techne and combining capabilities to lead the Spatial Biology market” said Dr. Ata Tuna Ciftlik, Chief Executive Officer of Lunaphore. “Our shared vision of tackling the translational and clinical research market, while using our complementary best-in-class spatial proteomics and transcriptomics products is going to make a great impact on our customers in advancing research. In addition, Bio-Techne’s global reach, and commercial and operational excellence will enable Lunaphore to accelerate its penetration into the high growth spatial biology market We’re now joining forces to be the largest spatial biology player.”